The association of high-density lipoprotein cholesterol with cancer incidence in type ii diabetes: A case of reverse causality?

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 9, 2013, Pages 1628-1633

  Morton, Jamie ^a,b   Ng, Martin K C ^a,b   Chalmers, John ^c   Woodward, Mark ^c   Mancia, Giuseppe ^f   Poulter, Neil R ^g   Marre, Michel ^h   Cooper, Mark E ^d   Zoungas, Sophia ^c,e  

^a Heart Research Institute   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISEASE DURATION; ETHNICITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT CANCER;

AUSTRALIA; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; INDAPAMIDE; MALE; MIDDLE AGED; NEOPLASMS; PERINDOPRIL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84884157339     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0149     Document Type: Article

References (23)

1. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation 1992;86: 1046-60.
2. Jacobs EJ, Gapstur SM. Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomarkers Prev 2009;18: 2805-6.
3. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 2814-21.
4. Kucharska-Newton AM, Rosamond WD, Schroeder JC, McNeill AM, Coresh J, Folsom AR. HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer 2008;61: 292-300.
5. Kucharska-Newton AM, Rosamond WD, Mink PJ, Alberg AJ, Shahar E, Folsom AR. HDL-cholesterol and incidence of breast cancer in the ARIC cohort study. Ann Epidemiol 2008;18: 671-7.
6. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst 2004;96: 1152-60.
7. Moorman PG, Hulka BS, Hiatt RA, Krieger N, Newman B, Vogelman JH, et al. Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status. Cancer Epidemiol Biomarkers Prev 1998;7: 483-8.
8. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment highdensity lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010;55: 2846-54.
9. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2011;60: 1094-102.
10. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33: 1674-85.
11. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287: 2570-81.
12. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370: 829-40.
13. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358: 2560-72.
14. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001;19:S21-8.
15. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. Acomparison with non-cancer subjects. Int J Clin Lab Res 2000;30: 141-5.
16. Vitols S, Gahrton G, Bjorkholm M, Peterson C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet 1985;2: 1150-4.
17. Fiorenza AM, Branchi A, Cardena A, Molgora M, Rovellini A, Sommariva D. Serum cholesterol levels in patients with cancer. Relationship with nutritional status. Int J Clin Lab Res 1996;26: 37-42.
18. EttingerWHJr, Harris T. Causes of hypocholesterolemia. Coron Artery Dis 1993;4: 854-9.
19. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK, et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 1994;14: 8-13.
20. Parks JS, Rudel LL. Alteration of high density lipoprotein subfraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. J Lipid Res 1985;26: 82-91.
21. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298: 784-8.
22. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157: 792-6.
23. Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010;30: 766-72.